The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection |
| Solubility | Soluble in aqueous buffer | Lipophilic chain lowers pure-water solubility |
| Long-term storage | -20 degrees Celsius or lower | With desiccant, protected from light |
| Short-term storage | 2 to 8 degrees Celsius | For dissolved aliquots |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection, often with mass confirmation |
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
National Institute for Occupational Safety and Health has determined non-regulatory recommended exposure limits (RELs) of 1 μg/m3 for carbon nanotubes and carbon nanofibers as background-corrected elemental carbon as an 8-hour time-weighted average (TWA) respirable mass concentration. Although CNT caused pulmonary inflammation and toxicity in mice, exposure to aerosols generated from sanding of composites containing polymer-coated MWCNTs, representative of the actual end-product, did not exert such toxicity. As of October 2016, single-wall carbon nanotubes have been registered through the European Union's Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) regulations, based on evaluation of the potentially hazardous properties of SWCNT. Based on this registration, SWCNT commercialization is allowed in the EU up to 100 metric tons. The type of SWCNT registered through REACH is limited to the specific type of single-wall carbon nanotubes manufactured by OCSiAl, which submitted the application.
== Last Universal Common Ancestor (LUCA) == Some authors equate models of the origin of life with LUCA, the Last Universal Common Ancestor of all extant life. This is a serious error resulting from failure to recognize that L refers to the last common ancestor, not to the first ancestor, which is much older: a large amount of evolution occurred before the appearance of LUCA. Gill and Forterre expressed the essential point as follows:
OpenAI's Sam Altman said OpenAI would "do the same," though without specifying implementation details. Later OpenAI disclosed six additional instances of "concerning model behavior" identified since March 2026. In late September 2026, leaders and senior officials from 20 countries and the European Union signed a non-binding declaration calling for AI to remain under "human direction, oversight and control," for common international safety standards, and for incident reporting, and agreed to further explore establishing a global oversight institution. Notably, the United States and China did not sign the declaration.
==== Dilution effect ==== Death-penalty supporters state that the claim that pancuronium dilutes the sodium thiopental dose is erroneous. Supporters argue that pancuronium and thiopental are commonly used together in everyday surgery and that if there were a dilution effect, it would be a known drug interaction. Drug interactions are a complex topic. Simplistically, drug interactions can be classified as synergistic or inhibitory. Drug interactions can happen in two ways: directly at the place where the drug works or indirectly when the drug is processed in the liver or removed by the kidney. Pancuronium and thiopental have different sites of action, one in the brain and one at the neuromuscular junction. Since the half-life of thiopental is 11.5 hours, the metabolism of the drugs is not an issue when dealing with the short time frame in lethal injections. The only other plausible interpretation would be a direct one, or one in which the two compounds interact with each other. Supporters of the death penalty argue that this theory does not hold true. They state that even if the 100 mg of pancuronium directly prevented 500 mg of thiopental from working, sufficient thiopental to induce coma would be present for 50 hours. In addition, if this interaction did occur, then the pancuronium would be incapable of causing paralysis.
Sources: en.wikipedia.org
The success of the submarine is inextricably linked to the development of the torpedo, invented by Robert Whitehead in 1866. His invention (essentially the same now as it was 140 years ago), allowed the submarine make the leap from novelty to a weapon of war. Prior to the development and miniaturization of sonar sensitive enough to track a submerged submarine, attacks were exclusively restricted to ships and submarines operating near or at the surface. Targeting of unguided torpedoes was initially done by eye, but by World War II analog targeting computers began to proliferate, being able to calculate basic firing solutions. Nonetheless, multiple "straight-running" torpedoes could be required to ensure a target was hit. With at most 20 to 25 torpedoes stored on board, the number of attacks a submarine could make was limited. To increase combat endurance starting in World War I submarines also functioned as submersible gunboats, using their deck guns against unarmed targets, and diving to escape and engage enemy warships. The initial importance of these deck guns encouraged the development of the unsuccessful Submarine Cruiser such as the French Surcouf and the Royal Navy's X1 and M-class submarines. With the arrival of anti-submarine warfare (ASW) aircraft, guns became more for defense than attack. A more practical method of increasing combat endurance was the external torpedo tube, loaded only in port. The ability of submarines to approach enemy harbours covertly led to their use as minelayers.
== See also == Island of stability Isotope § Nuclear properties and stability List of nuclides List of radioactive nuclides by half-life Primordial nuclide Stable nuclide Stable isotope ratio Table of nuclides
== Overdose == Zopiclone is sometimes used as a method of suicide. It has a similar fatality index to that of benzodiazepine drugs, apart from temazepam, which is particularly toxic in overdose. Deaths have occurred from zopiclone overdose, alone or in combination with other drugs. Overdose of zopiclone may present with excessive sedation and depressed respiratory function that may progress to coma and possibly death. Zopiclone combined with alcohol, opiates, or other central nervous system depressants may be even more likely to lead to fatal overdoses. Zopiclone overdosage can be treated with the GABAA receptor benzodiazepine site antagonist flumazenil, which displaces zopiclone from its binding site, thereby rapidly reversing its effects. Serious effects on the heart may also occur from a zopiclone overdose when combined with piperazine. Zopiclone is one of the most common drugs in drug poisoning suicides in elderly. When taken alone, it usually is not fatal, but when mixed with alcohol or other drugs such as opioids, or in patients with respiratory, or hepatic disorders, the risk of a serious and fatal overdose increases.
Sources: en.wikipedia.org
Simulating the systemic environment in tectonic fault zones within the Earth's crust, pressure cycling forms vesicles periodically, as well as random peptide chains which are selected for ability to integrate into the vesicle membrane. Further selection of vesicles for stability could lead to functional peptide structures, increasing vesicle survival rate.
== Further reading == Ahmad, Diana L. The Opium Debate and Chinese Exclusion Laws in the Nineteenth-century American West (University of Nevada Press, 2007). Drugs and Racism in the Old West. Armero and Rapaport. The Arts of an Addiction. Qing Dynasty Opium Pipes and Accessories (privately printed, 2005) Auerbach, Sascha. Race, Law and 'The Chinese Puzzle' in Imperial Britain. New York: Palgrave-Macmillan Press, 2009. Booth, Martin. Opium: A History. London: Simon & Schuster, Ltd., 1996. Chandra, Siddharth (2008). "Economic Histories of the Opium Trade". Archived from the original on September 28, 2013. Retrieved November 9, 2008. Chouvy, P.A. (2009). "Opium. Uncovering the Politics of the Poppy, London, I.B. Tauris (Cambridge, Harvard University Press: 2010)". Archived from the original on October 26, 2011. Retrieved October 20, 2009. Day, Horace B. (1868). The Opium Habit. de Quincey, Thomas (1821). Confessions of an English opium-eater. Standard Ebooks. Derks, Hans: History of the Opium Problem: The Assault on the East, ca. 1600–1950. Sinica Leidensia, 105. Leiden: Brill, 2012. ISSN 0169-9563. ISBN 978-90-04-22158-1 Dikötter, Frank, Lars Laamann, and Zhou Xun. Narcotic culture: a history of drugs in China Chicago: University of Chicago Press, 2004. Dormandy, Thomas (2012) Opium: Reality's Dark Dream, Yale University Press Fairbank, J.K. (1978) The Cambridge History of China: volume 10 part I, Cambridge, CUP Franck Daninos, L'opium légal produit en France, La Recherche, May 2005 Great Britain (1913).
Polatuzumab vedotin, sold under the brand name Polivy, is an antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). Polatuzumab is an antibody that targets CD79b, and vedotin is an agent that inhibits cell division by blocking the polymerisation of tubulin. It was developed by the Genentech subsidiary of Roche. The most common side effects include low levels of white blood cells (neutropenia), platelets (thrombocytopenia) and red blood cells (anemia); nerve damage (peripheral neuropathy); fatigue; diarrhea; fever; decreased appetite; and pneumonia. Polatuzumab vedotin was approved for medical use in the United States in June 2019, in Australia in October 2019, in the European Union in January 2020, and in Canada in November 2020.
==== In everyday life ==== The principal effect on BV in everyday life is the organism's current diet, although many other factors such as age, health, weight, sex, etc. all have an effect. In short any condition which can affect the organism's metabolism will vary the BV of a protein source. In particular, whilst on a high protein diet the BV of all foods consumed is reduced — the limiting rate at which the amino acids may be incorporated into the body is not the availability of amino acids but the rate of protein synthesis possible in cells. This is a major point of criticism of BV as a test; the test diet is artificially protein rich and may have unusual effects.
Sources: en.wikipedia.org
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.
Lyophilised powder is generally held at minus twenty degrees Celsius or lower for long-term storage. Once dissolved, aliquots are kept at two to eight degrees Celsius for short periods and should not be repeatedly frozen and thawed.
Photo-oxidation can modify tryptophan, methionine, and tyrosine residues, altering the structure. Amber glass containers or foil wrapping are routine measures to reduce light exposure.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.